Hood River Capital Management LLC Has $54.43 Million Stake in Enovis Corporation $ENOV

Hood River Capital Management LLC increased its position in Enovis Corporation (NYSE:ENOV) by 20.3% in the 2nd quarter, Holdings Channel reports. The firm owned 1,735,533 shares of the company’s stock after buying an additional 292,950 shares during the quarter. Hood River Capital Management LLC’s holdings in Enovis were worth $54,426,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Cetera Investment Advisers lifted its holdings in shares of Enovis by 30.9% during the 1st quarter. Cetera Investment Advisers now owns 24,591 shares of the company’s stock worth $940,000 after acquiring an additional 5,809 shares during the period. LPL Financial LLC boosted its holdings in Enovis by 40.1% during the first quarter. LPL Financial LLC now owns 48,949 shares of the company’s stock valued at $1,870,000 after purchasing an additional 14,013 shares in the last quarter. Natixis Advisors LLC raised its holdings in shares of Enovis by 4.0% in the 1st quarter. Natixis Advisors LLC now owns 20,157 shares of the company’s stock worth $770,000 after buying an additional 776 shares in the last quarter. US Bancorp DE lifted its position in shares of Enovis by 2.5% during the 1st quarter. US Bancorp DE now owns 19,031 shares of the company’s stock worth $727,000 after buying an additional 462 shares during the period. Finally, Vanguard Group Inc. grew its position in Enovis by 11.3% in the first quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock valued at $233,356,000 after acquiring an additional 621,069 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Price Performance

Shares of ENOV stock opened at $27.05 on Monday. Enovis Corporation has a 1 year low of $25.47 and a 1 year high of $49.38. The company has a current ratio of 2.22, a quick ratio of 1.16 and a debt-to-equity ratio of 0.66. The firm’s 50 day moving average is $30.46 and its 200-day moving average is $30.68. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -1.14 and a beta of 1.52.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Monday, January 8th. The company reported $0.59 earnings per share for the quarter. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The firm had revenue of $383.81 million during the quarter. Sell-side analysts forecast that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insider Activity

In other Enovis news, insider John Kleckner purchased 2,468 shares of the stock in a transaction dated Tuesday, November 25th. The stock was bought at an average price of $30.32 per share, for a total transaction of $74,829.76. Following the transaction, the insider directly owned 12,302 shares in the company, valued at $372,996.64. This represents a 25.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Damien Mcdonald purchased 6,457 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were acquired at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the purchase, the chief executive officer owned 102,753 shares of the company’s stock, valued at $3,182,260.41. The trade was a 6.71% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 2.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a research report on Wednesday, October 8th. Wells Fargo & Company lifted their target price on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $51.17.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.